August 11th 2020
The overall objective of this call topic is to shorten the path to RD diagnosis by using newborn/paediatric (infants during their first weeks of life) genetic screening; and, via application of advanced digital technologies that enable rare disease diagnosis / identification.
The latter might require consolidation of existing fragmented efforts.
In their proposals, applicants should:
- describe how the outputs of the project will contribute to the listed impacts and include, wherever possible, baseline, targets and metrics to measure impact.
- outline how the project plans to leverage the public-private partnership model to maximise impact on innovation, research & development; regulatory, clinical and healthcare practices, as relevant. This could include a strategy for engagement with patients, healthcare professional associations, healthcare providers, regulators, health technology assessment (HTA) agencies, payers etc., where relevant.
- describe how the project will impact the competitiveness and growth of companies including SMEs.
Detailed information about this call can be found here.